Novel Targeted Therapies in CLL Might Expand Treatment OptionsMedscapeOther studies with the novel agent in CLL are underway, including a phase 2 monotherapy study in patients with relapsed CLL and 17p deletions and combination studies with rituximab o…
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Phase 2 …MarketWatchThe phase 2 clinical trial presented at ASH has been expanded to include a treatment arm to assess the activity and tolerability of ADCETRIS in combination with Rituxan…
Emergent Bio (EBS) Issues Encouraging Update on TRU-016 Phase 1b in CLL …StreetInsider.com (subscription)Emergent Biosolutions (NYSE: EBS) announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy o…
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
Wall Street Journal Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with previously untreated … |
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
MarketWatch “Emergent is pleased with the data from Cohort 1 of this Phase 1b study that show the safety and activity of otlertuzumab in combination with rituximab,” said Scott C. Stromatt, M.D., senior vice president and chief medical officer, Emergent BioSolutions. |
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
Business Wire (press release) ROCKVILLE, Md.–(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in … |
Novel agent induced high response rate in high-risk CLL, SLLHealioA phase 2 monotherapy study in patients with relapsed del(17p) CLL is under way, as have combination studies with either rituximab (Rituxan, Genentech/Biogen Idec) or obinutuzumab (Gazyv…
This is Local London |
Obinutuzumab Tops Rituximab in CLL Trial
Cancer Network Obinutuzumab topped rituximab in a large chronic lymphocytic leukemia (CLL) trial of older, newly diagnosed patients, demonstrating improvements in response rate and progression-free survival (PFS), according to results presented at the 2013 American … Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patientsThe Oncology Report Dr. Goede on Obinutuzumab Versus Rituximab in CLLOncLive New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Healio –PR Newswire (press release) all 16 news articles » |
MedscapeThe Year in Rheumatology: 2013MedscapeNonclinical assessments demonstrating the similarity of the proposed biosimilar PF-05280586 and rituximab. Program and abstracts of the European League Against Rheumatism (EULAR) Congress 2013; June 12-15, …
|
Results Presented for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Monthly Prescribing Reference Gilead announced results from the Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to … Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent …Business Wire (press release) Gilead Announces Pivotal Phase 2 Results For Idelalisib In Refractory iNHLRTT News |